{"entity":{"id":"peter-schmid","kind":"person","name":"Peter Schmid","aka":[],"tldr":"Led KEYNOTE-522 and IMpassion130, the trials that brought immunotherapy into triple-negative breast cancer.","summary":"Peter Schmid was principal investigator of IMpassion130, the first positive immunotherapy trial in breast cancer, and of KEYNOTE-522, which showed neoadjuvant pembrolizumab with chemotherapy raises pathological complete response and improves event-free and overall survival in stage II-III TNBC. KEYNOTE-522 is now the global standard for early TNBC. He leads experimental cancer medicine at Barts and continues to run immunotherapy and ADC combination trials.","asOf":"2026-09-10","links":[{"label":"Barts Cancer Institute","url":"https://www.bartscancer.london/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Schmid%20P%5BAuthor%5D%20pembrolizumab%20triple-negative"}],"tags":["tnbc","immunotherapy","trialist"],"related":[],"cancers":["tnbc"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":["pd1","pdl1"],"drugs":["pembrolizumab","atezolizumab"],"companies":[],"institutions":["barts-cancer-institute"],"pathways":[],"terms":[],"trials":["keynote-522","impassion130"],"people":[],"bottlenecks":[],"keyPapers":["paper-keynote-522-nejm-2022"],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Cancer Medicine and Lead, Centre for Experimental Cancer Medicine, Barts Cancer Institute","institutionId":"barts-cancer-institute","specialisms":["Triple-negative breast cancer","Immunotherapy","Neoadjuvant therapy","Early drug development"],"profiles":[{"label":"Barts Cancer Institute","url":"https://www.bartscancer.london/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Schmid%20P%5BAuthor%5D%20pembrolizumab%20triple-negative"}],"papers":[{"title":"Pembrolizumab for early triple-negative breast cancer (KEYNOTE-522)","journal":"NEJM","year":2020,"doi":"10.1056/NEJMoa1910549"},{"title":"Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer (IMpassion130)","journal":"NEJM","year":2018,"doi":"10.1056/NEJMoa1809615"},{"title":"Overall survival with pembrolizumab in early-stage triple-negative breast cancer","journal":"NEJM","year":2024,"doi":"10.1056/NEJMoa2409932"},{"title":"KEYNOTE-522: adding pembrolizumab before and after surgery in early triple-negative breast cancer","journal":"New England Journal of Medicine","year":2022,"url":"https://doi.org/10.1056/NEJMoa2112651","doi":"10.1056/NEJMoa2112651"}],"orcid":"0000-0001-9817-5228"},"route":"/people/peter-schmid/","neighbours":{"cancer":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"target":[{"id":"pd1","kind":"target","name":"PD-1","route":"/targets/pd1/"},{"id":"pdl1","kind":"target","name":"PD-L1","route":"/targets/pdl1/"}],"drug":[{"id":"atezolizumab","kind":"drug","name":"Atezolizumab","route":"/drugs/atezolizumab/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}],"institution":[{"id":"barts-cancer-institute","kind":"institution","name":"Barts Cancer Institute / Barts Health NHS Trust","route":"/institutions/barts-cancer-institute/"}],"trial":[{"id":"impassion130","kind":"trial","name":"IMpassion130","route":"/trials/impassion130/"},{"id":"keynote-522","kind":"trial","name":"KEYNOTE-522","route":"/trials/keynote-522/"}],"paper":[{"id":"paper-capitello-290-capivasertib-paclitaxel-ann-oncol-2026","kind":"paper","name":"Capivasertib plus paclitaxel as first-line treatment for metastatic triple-negative breast cancer: results from the randomised, global phase III CAPItello-290 trial","route":"/key-papers/paper-capitello-290-capivasertib-paclitaxel-ann-oncol-2026/"},{"id":"paper-schmid-pakt-capivasertib-tnbc-jco-2020","kind":"paper","name":"Capivasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer: the PAKT trial","route":"/key-papers/paper-schmid-pakt-capivasertib-tnbc-jco-2020/"},{"id":"paper-tropion-breast02-ann-oncol-2026","kind":"paper","name":"Datopotamab deruxtecan in patients with untreated, advanced triple-negative breast cancer (TROPION-Breast02): a randomised, open-label, international, phase III trial","route":"/key-papers/paper-tropion-breast02-ann-oncol-2026/"},{"id":"paper-traina-enzalutamide-ar-tnbc-jco-2018","kind":"paper","name":"Enzalutamide for the treatment of androgen receptor-expressing triple-negative breast cancer","route":"/key-papers/paper-traina-enzalutamide-ar-tnbc-jco-2018/"},{"id":"paper-keynote-522-nejm-2022","kind":"paper","name":"KEYNOTE-522: adding pembrolizumab before and after surgery in early triple-negative breast cancer","route":"/key-papers/paper-keynote-522-nejm-2022/"},{"id":"paper-rugo-pd-l1-assay-comparison-impassion130-jnci-2021","kind":"paper","name":"PD-L1 Immunohistochemistry Assay Comparison in Atezolizumab Plus nab-Paclitaxel-Treated Advanced Triple-Negative Breast Cancer","route":"/key-papers/paper-rugo-pd-l1-assay-comparison-impassion130-jnci-2021/"}],"roadmap":[{"id":"tnbc-roadmap","kind":"roadmap","name":"Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem","route":"/roadmaps/tnbc-roadmap/"}]}}